Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells
- 1 July 1995
- journal article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 6 (5) , 438-445
- https://doi.org/10.1097/00001721-199507000-00011
Abstract
Glucocorticoids reduce prostaglandin synthesis in cultured vascular endothelium, but their effects on other haemostatic functions are unclear. We examined the effects of dexamethasone and cyclosporin A (CSA) on cultured human umbilical vein endothelial cells (HUVEC). One, 10 and 50 μg/ml CSA and 1 μg/ml dexamethasone (Dx) were added to the culture medium for 3 h, 3 days and 6 days and compared with HUVEC cultured in medium and serum alone. After assay of accumulated release of tissue type plasminogen activator (t-PA) and endothelin 1 (ET), cells were stimulated with 1 U/ml of human thrombin for 1 h and medium collected for RIA of 6-keto prostaglandin Fla (6-keto PGFlα), thrombospondin (TSP), von Willebrand factor (vWf) and ELISA of plasminogen activator inhibitor 1 (PAI-1). CSA at 1 μg/ml modestly reduced release of prostacyclin (PGI2) but had no reproducible effects on other metabolites. CSA at 10 and 50 μg/ml inhibited cell growth and thrombin stimulated release of PGI2 in a time-and dose-dependent manner. Inhibition of other endothelial metabolites was also observed at CSA 10 > μg/ml. Dexamethasone 1 μg/ml reduced both cell number and PGI2 release and increased thrombin stimulated release of vWf, TSP and PAI-1 with increases in t-PA and endothelin 1 in the medium. CSA 1 μg/ml and dexamethasone 1 μg/ml together were additive in reducing PGI2 release and increasing PAI-1 secretion. These observations suggest a role for endothelial dysfunction in the hypertensive and thrombotic complications observed in steroid treated patients with CSA potentially contributing to such complications.Keywords
This publication has 0 references indexed in Scilit: